Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
Diabetes Care. 2022; online ahead of print DOI: 10.2337/dc22-1318
Limited data exist regarding the cardiorenal efficacy and safety of SGLT2i in patients treated with intensive insulin regimens including short-acting insulin or high insulin doses. This post hoc analysis of DECLARE-TIMI 58 examined the effects of dapagliflozin vs placebo among 7,013 insulin users at baseline, of whom 4,650 were on regimens that included short-acting insulin and 1,339 were receiving insulin >1 IU/kg.
Dapagliflozin reduced CV death/HF hospitalisation among overall insulin users and consistently in patients on insulin regimens with or without short-acting insulin. In addition, there was no heterogeneity by insulin dose. The rate of MACE with dapagliflozin was similar irrespective of insulin regimen or dose. Dapagliflozin reduced the rate of adverse renal outcomes overall and consistently across subgroups of insulin users. The known safety profile of dapagliflozin was unchanged in patients on intensive insulin regimens.
Keywords:
